RxDoctor Payments Data

Sujitha Thottam

Adult Health · Jamaica, NYNPI 1487956140

Payments from drug & device makers

$8,960in general payments, 2019–2025

Across 302 payments — averaging $29.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Abbott$1K
  • Amgen$829
  • Corcept Therapeutics$811
  • AstraZeneca$595
  • Lilly USA, LLC$578
  • plus $4K from 28 others

What the payments were for

  • Food & beverage$8,960100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,960 in reported general payments places this provider in the 95th percentile of 3,828 adult health providers in New York.

See all adult health providers in New York

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide97$186,170
JardianceEmpagliflozin108$110,600
FarxigaDapagliflozin Propanediol51$57,803
JanumetSitagliptin Phos/Metformin Hcl43$55,869
ProliaDenosumab23$36,087
Tresiba Flextouch U-200Insulin Degludec40$33,015
TrulicityDulaglutide26$31,106
Tresiba Flextouch U-100Insulin Degludec25$21,653
JanuviaSitagliptin Phosphate17$17,077
Novolog FlexpenInsulin Aspart70$12,846
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog33$10,785
Lantus SolostarInsulin Glargine,hum.Rec.Anlog59$8,737
Ultra-Fine Mini Pen NeedlePen Needle, Diabetic57$5,311
Repaglinide58$2,120
Nano 2nd Gen Pen NeedlePen Needle, Diabetic34$1,820

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,336$186,17097 claims
MerckJanumet, Januvia$46$72,94660 claims
AstraZenecaFarxiga$595$57,80351 claims
AmgenProlia$829$36,08723 claims
Lilly USA, LLCTrulicity$578$31,10626 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid$486$1,06157 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,828 adult health providers in New York.

Other adult health in Jamaica

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →